The antibiotic trovafloxacin (TVX) has caused severe idiosyncratic hepatotoxicity in people, whereas levofloxacin (LVX) has not. Mice cotreated with TVX and lipopolysaccharide (LPS), but not with LVX and LPS, develop severe hepatocellular necrosis. Mice were treated with TVX and/or LPS, and hepatic gene expression changes were measured before liver injury using gene array. Hepatic gene expression profiles from mice treated with TVX/LPS clustered differently from those treated with LPS or TVX alone. Several of the probe sets expressed differently in TVX/ LPS-treated mice were involved in interferon (IFN) signaling and the janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway. A time course of plasma concentrations of IFN-g and interleukin (IL)-18, which directly induces IFN-g production, revealed that both cytokines were selectively increased in TVX/LPS-treated mice. Both IL-18 2/2 and IFN-g 2/2
Despite the rare occurrence of idiosyncratic adverse drug reactions (IADRs), they represent a serious hazard to public health and are an important issue for pharmaceutical companies and drug regulatory agencies. Current preclinical testing protocols fail to identify drugs that cause IADRs because predictive animal or in vitro models are lacking.
The liver is often a target of adverse drug reactions. A recent report found that hepatotoxicity from drugs has surpassed viral hepatitis as the leading cause of acute liver failure in the United States (Ostapowicz et al., 2002) . Despite the prevalence and threat of IADRs, the mechanisms underlying them are still unknown. We and others have hypothesized that an episode of inflammatory stress can render an individual susceptible to a normally nontoxic drug dose, thereby precipitating an IADR (Ganey et al., 2004; Roth et al., 2003; Tafazoli et al., 2005) . In concordance with this hypothesis, animal models have been developed in which rodents treated with lipopolysaccharide (LPS) to induce an inflammatory stress become sensitive to known IADR-causing drugs such as diclofenac, chlorpromazine, and trovafloxacin (Buchweitz et al., 2002; Deng et al., 2006; Luyendyk et al., 2003; Shaw et al., 2007; Waring et al., 2006) .
Trovafloxacin (TVX) is a fluoroquinolone antibiotic which has seen limited use due to its association with idiosyncratic hepatotoxicity in people. Rats given a nonhepatotoxic dose of LPS followed by a nontoxic dose of TVX developed significant hepatocellular injury . Levofloxacin (LVX) is a fluoroquinolone antibiotic not associated with hepatotoxicity. In accordance with the lack of hepatotoxicity seen in people, LVX/LPS coexposure was nontoxic to rats.
Global gene expression analysis of livers at a time of maximal hepatotoxicity revealed distinct clustering of LPS/ TVX-treated rats. We showed recently that mice cotreated with TVX and LPS also develop hepatocellular necrosis. Similar to the rat model, LVX did not interact with LPS to cause liver injury . Here we test the hypothesis that at a time before the onset of liver injury, TVX/LPS treatment of mice leads to a distinct pattern of gene expression.
In testing this hypothesis, we identified several genes involved in interferon (IFN) signaling that were changed by TVX/LPS coexposure. IFN-c is a proinflammatory cytokine that plays a key role in both the innate immune system and modulation of the adaptive immune system (Varma et al., 2002) . It is a critical mediator of liver injury from several xenobiotic agents (Kim et al., 2003; Kusters et al., 1996; Liu et al., 2004) . Accordingly, we hypothesized that IFN-c plays a critical role in TVX/LPS-induced liver injury and investigated its influence on the induction of other proinflammatory cytokines.
MATERIALS AND METHODS
Materials. Unless otherwise noted, all reagents were purchased from Sigma Chemical Co. (St Louis, MO) . LPS derived from Eschericia coli serotype O55:B5 (Lot 075K4038) was used for these studies. The LPS had an activity of 3.3 3 10 6 EU/mg as determined using a colorimetric, Limulus amebocyte lysate assay purchased from Cambrex Corp. (Kit 50-650U; East Rutherford, NJ).
Animals. All animals received humane care, and all studies complied with Michigan State University guidelines. Male C57Bl/6J mice (Jackson Laboratory, Bar Harbor, ME) were used for the experiments unless otherwise noted. IL-18 À/À mice and C57/Bl6 wild-type controls were purchased from Jackson Laboratory. IFN-c À/À female Balb/C mice were a kind gift from Dr
Alison Bauer (MSU, East Lansing, MI), and corresponding female Balb/C control mice were purchased from Jackson Laboratory. For all experiments, mice were allowed to acclimate for 1 week in a 12-h light/dark cycle and used between 9 and 11 weeks of age. Animals were given continual access to bottled spring water and were fed a standard chow (Rodent Chow/Tek8640; Harlan Teklad, Madison, WI).
Study design and sample collection. In a previous study, mice cotreated with nonhepatotoxic doses of TVX and LPS developed liver injury . The dose of LVX was chosen to approximate the ratio of TVX/ LVX doses used clinically in humans. Mice were fasted for 12 h before each experiment. TVX (150 mg/kg), LVX (375 mg/kg), or their saline vehicle (veh) was administered to mice by oral gavage and then mice were given LPS (2.0 3 10 6 EU/kg, ip) 3 h later. Food was returned immediately after LPS administration. Mice were anesthetized with sodium pentobarbital (50 mg/kg, ip) at various times and sacrificed by exsanguination. The left lateral liver lobe was fixed in 10% neutral buffered formalin and blocked in paraffin within 72 h. The right medial liver lobe was flash frozen in liquid nitrogen for total RNA isolation.
Alanine aminotransferase activity and histopathology assessment. Plasma alanine aminotransferase (ALT) activity was measured spectrophotometrically using Infinity ALT reagent purchased from Thermo Electron Corp. (Louisville, CO). Formalin-fixed liver lobes were processed and embedded in paraffin. Paraffin sections were cut at 5 lm and stained with hematoxylin and eosin.
RNA isolation. Frozen liver samples (50 mg of tissue per sample) were immediately added to 2 ml of TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA). In all, 1 ml of the tissue homogenate was transferred to a microfuge tube, and total RNA was extracted with chloroform followed by nucleic acid precipitation with isopropanol. The pellet was washed with 80% ethanol and resuspended in molecular biology grade water. Nucleic acid concentration was determined spectrophotometrically at 260 nm (Smart-Spec; Bio-Rad Laboratories, Hercules, CA), and RNA integrity was evaluated using an Agilent bioanalyzer (Agilent Technologies, Model 2100, Foster City, CA).
Gene array analysis. Microarray analysis was performed using the standard protocol provided by Affymetrix, Inc. (Santa Clara, CA). Briefly, approximately 5 lg of total RNA was reversed transcribed into cDNA using a Superscript II Double-Strand cDNA Synthesis Kit (Invitrogen Life Technologies). The primer used for the reverse transcription reaction was a modified T7 primer with 24 thymidines at the 5# end (Affymetrix). The sequence was 5#-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(dT)24-3#. cDNA was purified via phenol/chloroform/isoamyl alcohol (Invitrogen Life Technologies) extraction and ethanol precipitation. Biotin-labeled cRNA was synthesized according to the manufacturer#s instructions from the cDNA using the Enzo RNA Transcript Labeling Kit (Affymetrix). The labeled cRNA was then purified using RNeasy Kits (Qiagen, Valencia, CA). cRNA concentration and integrity were evaluated. Approximately 20 lg of cRNA was then fragmented in a solution of 40mM Tris-acetate, pH 8.1, 100mM potassium acetate, and 30mM magnesium acetate at 94°C for 35 min. Fragmented, labeled cRNA was hybridized to an Affymetrix mouse genome array, 430A 2.0, which contains sequences corresponding to roughly 22,600 transcripts, at 45°C overnight using an Affymetrix Hybridization Oven 640. The array was subsequently washed and stained twice with strepavidin-phycoerythrin (Molecular Probes, Eugene, OR) using a Gene-Chip Fluidics Workstation 400 (Affymetrix). The array was then scanned using the Affymetrix GeneChip Scanner 3000.
Hepatic neutrophil accumulation. Polymorphonuclear leukocyte (PMN) immunohistochemistry was performed on 5-lm slices of paraffin-embedded liver sections as described previously (Yee et al., 2003) . PMNs were stained using a rabbit anti-PMN immunoglobulin isolated from the serum of rabbits immunized with rat PMNs (Hewett et al., 1992) . Hepatic PMN accumulation was quantified by counting the number of PMNs in 6-10 randomly selected, high-power fields (3400) for each liver.
Plasma cytokine measurements. The plasma concentrations of IFN-c, interleukin (IL)-18, IL-6, IL-10, macrophage inflammatory protein (MIP)-1a, keratinocyte chemoattractant (KC), MIP-2, monocyte chemoattractant protein-1 (MCP-1), vascular endothelial growth factor (VEGF), tumor necrosis factor-a (TNF-a), and IL-1b were measured using bead-plex kits purchased from BioRad Laboratories and a Bio-Plex 200 system (Hercules, CA).
Statistical methods. ALT activity and plasma protein concentration results are presented as mean ± SEM. A one-, two-, or three-way ANOVA was used as appropriate after data normalization. All pairwise comparisons were made using Dunn method. The criterion for significance was p < 0.05.
The results of the microarrays were analyzed using Rosetta Resolver error models, and ratios were built for each treatment array compared to the Veh/Veh control using the Resolver System. This analysis calculated a p value for every gene's fold change relative to Veh/Veh using the Rosetta Resolver error model (Rajagopalan, 2003) . The gene expression change was considered significant if it had a p value < 0.001. Genes were considered regulated if the p value was <0.001 for two of three Veh/Veh-, two of three TVX/Veh-, two of three LVX/ Veh-, four of five Veh/LPS-, three of four LVX/LPS-, five of seven TVX/ LPS-treated mice. Average link heuristic criteria and the Euclidean distance metric for similarity measure were used to perform the agglomerative cluster analysis of the treatment arrays using Rosetta Resolver software. Gene expression profile analysis was done using Ingenuity pathway analysis purchased from Ingenuity Systems (Redwood, CA).
RESULTS

Development of Hepatocellular Injury after TVX/LPS but not LVX/LPS Coexposure
The time course of hepatocellular injury was examined to determine the time of the onset of liver injury. Treatment with TVX, LVX, LPS, or LVX/LPS did not increase plasma ALT activity (Fig. 1) . TVX/LPS coexposure, however, caused a significant increase in plasma ALT activity as early as 4.5 h which continued to increase through 15 h (Fig. 1) .
Hepatic Global Gene Expression Changes before the Onset of Hepatotoxicity
Hepatic gene expression was evaluated at 3 h after LPS, a time prior to the onset of liver injury. Analysis of Affymetrix Genechip 430 2.0 Array data identified probe sets defined as regulated relative to Veh/Veh-treated mice, and these were subjected to hierarchical clustering analysis (Fig. 2) . Within the cluster of LPS-treated mice, LVX/LPS-and Veh/LPS-treated IFNc-DEPENDENT IADR-LIKE LIVER INJURY mice were distinguished from TVX/LPS-treated mice (Fig. 2) . Thus, hierarchical clustering applied to gene expression analysis was able to distinguish TVX/Veh from LVX/Vehtreated mice. In addition, at a time before liver injury, a separate cluster occurred for TVX/LPS-treated mice, the only treatment that produced hepatotoxicity.
Gene Expression Changes within TVX/LPS, TVX/Veh, and Veh/LPS Treatment Groups
The gene expression changes in the TVX/LPS-treated group are potentially important because they can be anchored to hepatotoxicity. TVX/LPS treatment resulted in 2156 gene expression changes compared to Veh/Veh-treated mice. The gene expression changes induced by TVX/LPS treatment were compared to those induced by TVX or LPS alone, revealing a large number of genes changed selectively in TVX/LPStreated mice (Fig. 3) . TVX/Veh-treated mice had a roughly equal number of hepatic genes upregulated as downregulated. In contrast, Veh/LPS treatment caused a greater number of genes to be upregulated than downregulated. The majority (580/773) of the TVX/LPS treatment-selective genes were downregulated. In addition, a large number of genes (983) were commonly regulated by TVX/LPS and Veh/LPS treatment. TVX/LPS and TVX/Veh treatments resulted in 619 similarly regulated genes. As expected, there were relatively few genes regulated by both TVX/Veh and Veh/LPS treatments which were not also affected by TVX/LPS treatment.
Several Gene Expression Changes in TVX/LPS-Treated Mice Are Involved in IFN Signaling
Gene expression changes in the TVX/LPS-treated mice were of interest due to the development of hepatotoxicity and were examined further. To do this, a list of genes expressed differently (p < 0.001) in the TVX/LPS-treated mice compared to all other treatment groups (Veh/Veh, TVX/Veh, LVX/Veh, Veh/LPS, and LVX/LPS) was created using TVX/LPS treatment as the baseline for ratio building. In all, 254 probe sets were selectively altered by TVX/LPS treatment; of these probe sets, 142 represented functional genes as determined by Ingenuity Systems analysis. A full list of these 142 TVX/LPSselective genes can be found in Supplementary Table 1. The 142 genes selectively changed in expression by TVX/ LPS were analyzed using Ingenuity pathway analysis to determine highly affected pathways. Table 1 is a list of pathways impacted by the genes selectively altered by TVX/ LPS treatment in order of increasing p values. Pathways with p values > 0.1 were excluded from the list. In addition to the p values, the fraction (ratio) of genes affected within each pathway is reported.
Of the pathways affected, two that are involved in several models of liver injury and had high ratios and low p values were JAK/STAT signaling and IFN signaling (Table 1) . Several pathways were highly affected; however, a driving force for the further investigation of janus kinase/signal transducers and activators of transcription (JAK/STAT) and IFN signaling was their involvement in other models of inflammatory tissue injury. Type I and II IFNs signal via specific receptors through JAK/ STAT signaling within cells (Stark et al., 1998) . To examine further the potential role of IFNs in TVX/LPS-induced gene expression changes, genes in the set of 142 TVX/LPS-selective genes were examined for their relationship to IFNs. Of the 142 genes, 26 (18.3%) are regulated by IFNs (Table 2) . Of these IFN-regulated genes, all but three were increased in expression. The majority of these genes were regulated by IFN-c. A number of the genes have potential importance in the development of hepatotoxicity by being proapoptotic, chemokines, proinflammatory or involved in immune responses ( Table 2 ). The expression of a large portion of TVX/LPS-selective genes can be increased by IFN-c; accordingly, we examined the role of IFNc in TVX/LPS-induced liver injury.
Time Course of Plasma Concentrations of IL-18 and IFN-c
IL-18 induces the production of IFN-c in several cell types. Neither TVX nor LVX increased plasma concentrations of IL-18 or IFN-c when given alone. LPS treatment caused a significant increase in both IL-18 and IFN-c plasma concentrations at all times measured (Figs. 4A and B) . TVX treatment prior to LPS caused a further increase in plasma concentrations of IL-18 and IFN-c at both 4.5 and 6 h (Figs. 4A and B). In contrast, LVX did not affect either plasma IL-18 or IFN-c induction by LPS (Figs. 4A and B) .
TVX/LPS-Induced Hepatocellular Injury in IL-18
À/À Mice
To explore the role of IL-18 in TVX/LPS-induced liver injury in mice, wild-type and IL-18 À/À mice were treated with TVX/ LPS. IL-18 À/À mice had significantly reduced plasma ALT activity compared to the wild-type controls (Fig. 5A ). In corroboration with the ALT values, TVX/LPS treatment resulted in midzonal hepatocellular necrosis in wild-type control mice (Fig. 5B) , which was less extensive in IL-18 À/À mice (Fig. 5C ).
TVX/LPS-Induced Liver Injury in IFN-c À/À Mice
To examine the role of IFN-c in TVX/LPS-induced liver injury, wild-type and IFN-c À/À female Balb/C mice were treated with TVX/LPS. Female Balb/C wild-type and IFN-c À/À mice were used based on the availability of the IFN-c À/À mice. The gender and strain difference did not affect the ability of TVX and LPS to synergize to cause liver injury. Additionally, IL-18 induction of the IFN-c pathway is common to both strains. TVX or LPS treatment alone did not cause hepatocellular injury in female Balb/C mice (data not shown). TVX/LPS treatment resulted in significant liver injury in the female Balb/ C mice, as seen in male C57/Bl6 mice. In IFN-c À/À mice, the TVX/LPS-induced increase in plasma ALT activity was markedly attenuated compared to wild-type controls (Fig. 6A) . Midzonal coagulative necrotic lesions obvious in wild-type mice were not seen in IFN-c À/À mice (Figs. 6B and 6C).
TVX/LPS-Induced Hepatic Neutrophil Accumulation and Proinflammatory Cytokines in IFN-c À/À Mice
Hepatic PMN accumulation and plasma concentrations of several cytokines and chemokines were measured at a time before the onset of liver injury in wild-type controls and in IFN-c À/À mice. Plasma ALT activity values were equivalent to baseline for both wild-type and IFN-c À/À mice (Fig. 8A) . Hepatic PMN accumulation was also similar in IFN-c À/À mice compared to wild-type mice 6 h after TVX/LPS treatment (Fig. 7) . The plasma concentrations of IL-6, MCP-1, IL-10, KC, MIP-2, MIP-1a, and VEGF were similar in wild-type and IFN-c À/À mice given TVX/LPS (data not shown). In contrast, TVX/LPS-treated IFN-c À/À mice had significantly reduced plasma concentrations of TNF-a, IL-18, and IL-1b compared to TVX/LPS-treated wildtype mice (Figs. 8B-D) .
DISCUSSION
This study confirmed previous results that TVX pretreatment, but not LVX pretreatment, interacted with an inflammatory stress induced by LPS to cause liver injury in mice. We extended this to define the early time course of hepatocellular injury as measured by plasma ALT activity. TVX/LPS-treated mice had a small but significant increase in plasma ALT activity as early as 4.5 h after LPS, whereas there was not a significant increase in plasma ALT activity in any   FIG. 3 . Venn diagram depiction of probe set regulation of TVX/Veh-, Veh/LPS-, and TVX/LPS-treated mice relative to Veh/Veh-treated controls. Mice were treated with TVX and/or LPS as described in the Materials and Methods. Three hours after LPS administration, total RNA was isolated from the liver, and gene expression was evaluated using Affymetrix Genechip 430 2.0 Arrays. The number of probe sets increased or decreased relative to Veh/ Veh-treated mice is shown. Probe sets were defined as regulated if p < 0.001.
IFNc-DEPENDENT IADR-LIKE LIVER INJURY
other treatment group at any time measured (Fig. 1) . Based on these results, hepatic gene expression changes were examined at 3 h, a time just before the onset of liver injury.
Similar to results obtained in LPS/TVX-treated rats after the onset of liver injury , we observed that TVX/LPS coexposure resulted in unique gene expression changes in mice prior to the onset of liver injury (Fig. 2) . The distinct gene expression profiles were observed despite differences in species, timing, and routes of LPS and TVX administrations in the two studies . It is possible that some of the gene expression changes following TVX/LPS coexposure reflect an adaptive response to the toxic effects of TVX/LPS. However, these results in mice suggest that global gene expression change is an earlier marker of liver toxicity than plasma ALT activity in this model.
Although numerous groups of genes might be involved in injury, the set of gene expressions selectively affected by TVX/ LPS was chosen as a starting point for mechanistic analysis. Whereas TVX treatment alone caused an equivalent number of genes to be upregulated as downregulated, the majority of TVX/ Note. FXR, farnesoid X receptor; RXR, retinoid X receptor; NRF2, NE-F2-related factor; NF-jB, nuclear factor-kappa B; LXR, liver X receptor; PI3K, phosphoinositide 3-kinase/Akt; PDGF, platelet-derived growth factor; VDR, vitamin D receptor; TGF-b, transforming growth factor beta; PTEN, phosphatase and tensin homolog; Mice were treated as described in the Materials and Methods. Three hours after LPS administration, RNA was isolated from the liver, and gene expression was evaluated using Affymetrix Genechip 430 2.0 Array. Probe sets were defined as regulated if p < 0.001. The 254 gene-associated probe sets changed by TVX/LPS coexposure when compared to all other treatment groups were analyzed by Ingenuity pathway analysis. Of these 254 probe sets, 142 were identified as functional genes. The pathways highly affected (p < 0.1) are listed along with the ratio of the number of genes changed selectively by TVX/LPS to the total number of genes in the pathway as identified by the Ingenuity database. The specific genes selectively changed by TVX/LPS that are in each pathway are listed. Some of these genes are involved in more than one pathway and are, therefore, listed more than once. JAK/STAT and IFN signaling pathways discussed in the text are bolded.
LPS-selective genes were downregulated in expression. TVX has the potential to interact with eukaryotic topoisomerases (Anderson and Osheroff, 2001) , and this might explain the reduced expression of a large number of genes. There were several pathways affected by TVX/LPS treatment that suggest that TVX magnifies the inflammatory response induced by LPS treatment (Table 1 ). This finding is consistent with the finding that TVX pretreatment enhances the plasma concentrations of several proinflammatory cytokines induced by LPS (Shaw et al., 2008) . Of the pathways impacted by TVX/LPS treatment, JAK/ STAT and IFN signaling pathways are involved in numerous models of inflammatory tissue injury and were highly affected.
The actions of IFN-c are exerted through the activation of the JAK/STAT pathway (Stark et al., 1998) . Of the 142 TVX/ LPS selectively expressed genes, 26, or 18%, can be regulated by IFNs. Furthermore, a significant number of these genes have roles in functions related to hepatotoxicity, such as apoptosis, leukocyte migration, proinflammatory cytokine production and immune response. Moreover, despite the expression of a large number of TVX/LPS-selective genes being downregulated, nearly all (23/26) the IFN-regulated TVX/LPS-selective genes were upregulated. This suggests an increase in IFN signaling. The majority of these genes are known to be regulated by IFN-c, rather than by IFN-a or IFN-b. Interferon regulatory factor-1 (IRF-1), one of the genes selectively upregulated by TVX/LPS, encodes for a transcription factor activated as a result of JAK/ STAT activation by IFN-c (Stark et al., 1998) . This pathway is activated in several other models of liver injury, including concavalin A, acetaminophen, ischemia/reperfusion, and LPS/ galactosamine (Jaruga et al., 2004; Lee et al., 2007; Liu et al., Note. MHC, major histocompatibility complex; MAPK, mitogen-activated protein kinase; JNK, c-Jun N-terminal kinase; SMT3, yeast small ubiquitin-like modifier; TLR, toll-like receptor; Mice were treated as described in the Materials and Methods. Three hours after LPS administration, RNA was isolated from the liver, and gene expression was evaluated using Affymetrix Genechip 430 2.0 Array. Probe sets were defined as regulated if p < 0.001. Of the 142 genes changed selectively by TVX/LPS coexposure, the 26 listed have been reported to be regulated by IFNs as determined by Ingenuity pathway analysis. : symbolizes increased in expression selectively after TVX/LPS coexposure; ; symbolizes decreased in expression selectively after TVX/LPS coexposure.
2004; Tsung et al., 2006) . However, the role of IFN-c or IL-18 has not been examined in a model of liver injury from drug/ inflammation interaction; therefore, the role of these cytokines was explored in TVX/LPS-induced injury.
The first step was to measure the plasma concentrations of IL-18 and IFN-c. IL-18 stimulates IFN-c production (Tsutsui et al., 2000) . The plasma concentrations of both IL-18 and IFN-c were selectively increased by TVX/LPS treatment (Figs.  4A and B) . This enhancement and prolongation of the IFN-c induction by LPS has not been shown previously in any drug/ LPS coexposure model of liver injury. The mechanism by which this interaction occurs is unknown. However, we reported previously that TVX pretreatment prolongs the LPSinduced plasma TNF-a peak . It is thus possible that this prolongation of the TNF-a peak drives the prolongation of the plasma IFN-c peak. (Fig. 6 ) having lower plasma ALT activity in response to TVX/LPS treatment than C57Bl/6 wild-type controls (Fig. 5) , the degree of liver injury was equivalent based on histopathologic examination. It is unknown whether the difference seen in the magnitude of ALT activity increase in response to TVX/LPS was due to a strain or gender difference. Regardless, the pathway by which IL-18 increases IFN-c is common to both male C57Bl/ 6 and female Balb/C mice. Thus, the observation that both male C57Bl/6 IL-18 À/À mice and female Balb/C IFNc À/À mice were protected from TVX/LPS-induced liver injury suggests that the importance of this pathway in TVX/LPS-induced liver injury is not gender or strain specific. Therefore, despite the possibility that some of the mechanisms underlying TVX/LPS-induced liver injury in Balb/C and C57Bl/6 mice might be different, the IFN-c-driven pathway seems to be involved in the pathogenesis in both strains.
Several inflammatory cytokines and chemokines were measured in wild-type and IFN-c À/À mice treated with TVX/ 
LPS at a time near the onset of liver injury. At this time, there was not a significant difference in plasma ALT activity between wild-type and IFN-c À/À mice (Fig. 8A) . This eliminates the possibility that a difference seen in plasma concentrations of cytokines was due to a difference in injury. The plasma concentrations of several cytokines were unchanged, but TNF-a, IL-1b, and IL-18 were significantly reduced in IFN-c À/À mice. Previously, TNF-a inhibition attenuated TVX/LPS-induced liver injury . IFN-c enhances the production and release of TNF-a, as shown in vitro (Kawada et al., 1991) . In vivo, IFN-c induction of TNF-a production is mediated by IRF-1 (Senaldi et al., 1999) , a transcription factor selectively upregulated in TVX/LPS-treated mice (Table 2) . Interestingly, TNF-a inhibition reduced the TVX/LPS-induced increase in IFN-c (unpublished data), suggesting that each of these cytokines regulates the expression of the other. Additionally, IFN-c À/À mice had reduced levels of IL-1b and IL-18. These cytokines exist as proforms of the proteins in cells and are cleaved by caspase 1 to their active forms. The mRNA levels of IL-1b and IL-18 were unchanged in gene expression analysis. Therefore, we hypothesize that IFN-c positively feeds back to increase caspase 1 activity either directly or indirectly. The consequent increase in IL-18 could then cause more production of IFN-c, potentially resulting in a proinflammatory vicious cycle.
IFN-c causes apoptosis in primary hepatocytes (Kano et al., 1997) , and it is possible that TVX directly sensitizes hepatocytes to IFN-c-induced cell death. The protein synthesis inhibitor, cycloheximide, sensitizes cells to IFN-c-induced cell death (Beppu et al., 2003) . TVX can act to inhibit eukaryotic topoisomerase (Anderson and Osheroff, 2001) . Accordingly, topoisomerase inhibition by TVX might inhibit protein synthesis and thereby render hepatocytes sensitive to IFN-cinduced cell death. Additionally, TVX enhanced the LPSinduced increases in both TNF-a and IFN-c, which synergize to cause primary hepatocyte death (Adamson and Billings, 1993) . It is also possible that TVX acts directly on hepatocytes to enhance TNF-a/IFN-c-induced cell death.
In addition to effects on other proinflammatory cytokines, IFN-c can play a direct role in the regulation and activation of many cell types that might be involved in liver injury. For example, PMN activation is critical for TVX/LPS-dependent liver injury (Shaw et al., 2008) . Both TNF-a and IFN-c can increase PMN activation in vitro as measured by oxidative burst and differential gene expression (Dri et al., 1999; Edwards et al., 1988; Ellis and Beaman, 2004; Suzuki et al., 1990) . Although PMN accumulation after TVX/LPS cotreatment was unchanged in IFN-c À/À mice, it is possible that activation of accumulated PMNs was decreased in these mice. PMNs have receptors capable of binding IFN-c and activating JAK/STAT signaling (Finbloom, 1990) . Both IFN-c and TNF-a can prime PMNs to enhance activation following a second stimulus (Galligan and Yoshimura, 2003; Walker and Ward, 1992) . Accordingly, IFN-c À/À mice, in which IFN-c and TNF-a production is decreased, might have reduced PMN activation due to a lack of this priming. In addition, IFN-c plays a role in the activation of CD8þ T cells and macrophages (Adams and Hamilton, 1984; Boehm et al., 1997) . Accordingly, it is possible that IFN-c is involved in hepatotoxicity by activating one or more of these cell types which might play a role in the pathogenesis.
The results of current and previous studies have implicated TNF-a , neutrophil activation (Shaw et al., 2008) , IL-18 (Fig. 5) , and IFN-c (Fig. 6 ) in the pathogenesis of TVX/LPS-induced liver injury. The neutralization of TNF-a caused a reduction in the TVX/LPS-induced increases of IL-18 and IFN-c (data not shown), suggesting that the induction of IL-18 and IFN-c following TVX/LPS coexposure is TNF-adependent. In turn, IFN-c positively feeds back to increase TNF-a production (Fig. 8) . Hypothesized pathways (dotted lines) and mechanisms for which we have evidence (solid lines) are illustrated in Figure 9 in context of their roles in TVX/LPS-induced liver injury. The full extent to which these mediators interact with one another is a topic of current investigation.
In summary, LPS interacts with TVX, but not LVX, to cause liver injury in mice. That hepatotoxicity only occurred for the drug with IADR potential in humans raises the possibility that inflammatory stress might play a role in the pathogenesis of idiosyncratic liver injury caused by TVX in people. Gene expression analysis revealed distinct clustering by treatment at a time before the onset of liver injury. A small group of genes was identified which changed in expression only after TVX/ LPS treatment compared to all other treatment groups. Of these genes, a large number were related to IFN signaling. This observation led to experiments that demonstrated the involvement of IL-18 and IFN-c in the pathogenesis of TVX/ LPS-induced liver injury in mice. 
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